Knowledge hub

News

Ardigen and DKFZ Research Groups Collaborate to Evaluate the TCR-based Therapies (TCR-Ts)

Ardigen at SLAS International Conference & Exhibition 2023
Meet Ardigen phenAID platform
Ardigen at PMWC 2023
Mariola Fotin-Mleczek, PhD, Has Joined Ardigen’s Scientific Board
Ardigen supports JUMP-CP Consortium – The World’s Largest Public Cell Painting Dataset
Agnieszka Blum, MD, PhD, Promoted to the Ardigen Management Board
Prof. Dr. med. Michael Schmitt, MHBA in Ardigen’s Scientific Board
Łukasz Dutkiewicz, PhD Welcomed in Ardigen as a Business Development Director
News

Discover Our Gene Regulation Platform

Unconventional γδ T cells as allogeneic cellular products in immunotherapies for cancer.
Boost Your Way to Successful Therapy: AI for Drug Discovery Days
Ardigen – New Corporate Identity
Happy Holidays 2021
Prof. Olivera Finn joined Ardigen’s Scientific Board
Ardigen has received funding for the development of the AI-powered Microbiome Platform.
Gut microbiota’s road to clinical utilization. From bathroom to bedside.
Off-the-Shelf allogeneic cellular immunotherapies for cancer